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microRNA Expression Levels Change
in Neonatal Patients During and After
Exposure to Cardiopulmonary Bypass
Lance Hsieh , BA*; Lan N. Tu, PhD*; Alison Paquette, PhD;* Quanhu Sheng, PhD; Shilin Zhao, PhD;
Douglas Bittel , PhD; James O’Brien , MD; Kasey Vickers , PhD; Peter Pastuszko, MD; Vishal Nigam

, MD

BACKGROUND: The systemic inflammation that occurs after exposure to cardiopulmonary bypass (CPB), which is especially
severe in neonatal patients, is associated with poorer outcomes and is not well understood. In order to gain deeper insight
into how exposure to bypass activates inflammatory responses in circulating leukocytes, we studied changes in microRNA
(miRNA) expression during and after exposure to bypass. miRNAs are small noncoding RNAs that have important roles in
modulating protein levels and function of cells.
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METHODS AND RESULTS: We performed miRNA-sequencing on leukocytes isolated from neonatal patients with CPB (n=5) at
7 time points during the process of CPB, including before the initiation of bypass, during bypass, and at 3 time points during the first 24 hours after weaning from bypass. We identified significant differentially expressed miRNAs using generalized
linear regression models, and miRNAs were defined as statistically significant using a false discovery rate–adjusted P<0.05.
We identified gene targets of these miRNAs using the TargetScan database and identified significantly enriched biological
pathways for these gene targets. We identified 54 miRNAs with differential expression during and after CPB. These miRNAs
clustered into 3 groups, including miRNAs that were increased during and after CPB (3 miRNAs), miRNAs that decreased
during and after CPB (10 miRNAs), and miRNAs that decreased during CPB but then increased 8 to 24 hours after CPB. A
total of 38.9% of the target genes of these miRNAs were significantly differentially expressed in our previous study. miRNAs
with altered expression levels are predicted to significantly modulate pathways related to inflammation and signal transduction.
CONCLUSIONS: The unbiased profiling of the miRNA changes that occur in the circulating leukocytes of patients with bypass provides deeper insight into the mechanisms that underpin the systemic inflammatory response that occurs in patients
after exposure to CPB. These data will help the development of novel treatments and biomarkers for bypass-associated
inflammation.
Key Words: cardiopulmonary bypass ■ inflammation ■ microRNA ■ neonate

S

urgical palliation/repair of congenital heart defects
is associated with significant morbidity, mortality,
and cost. Neonatal patients are particularly at
risk, having a 10% mortality and a 30% complication
rate.1,2 The majority of pediatric open-heart surgeries
require the patient to be supported by cardiopulmonary bypass (CPB) to give the surgeon a bloodless field

to operate in, while also minimizing ischemic damage
to the body. However, patients with CPB experience
significant post-
CPB inflammation—
which includes
increased cytokine levels, inflammatory cell infiltration, vascular leak, and multiorgan dysfunction. In
neonates recovering from complicated cardiac surgeries, increased cytokine levels are associated with high
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CLINICAL PERSPECTIVE
What Is New?

• We address a critical gap in knowledge by systematically mapping how microRNAs, small
noncoding RNAs that play an important role in
regulating genes, change in the circulating leukocytes of neonatal patients during and after
cardiopulmonary bypass.
• The data presented in this publication will
advance the understanding of the molecular mechanisms that drive cardiopulmonary
bypass–associated inflammation and facilitate
efforts to reduce cardiopulmonary bypass–
associated morbidity and mortality.

What Are the Clinical Implications?

• Our findings have translational implications for
patients with cardiopulmonary bypass and for
other conditions that involve blood being exposed to increased shear stresses, such as
ventricular assist devices, extracorporeal live
support, and hemodialysis.

Nonstandard Abbreviations and Acronyms
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CPB
DEG
FDR
KEGG

cardiopulmonary bypass
differentially expressed gene
false discovery rate
Kyoto Encyclopedia of Genes and
Genomes
MAPK mitogen-activated protein kinase
miRNA microRNA

mortality and extended intensive care stays3; however,
the molecular mechanisms that underlie this inflammatory response are not fully understood.
In an effort to understand how CPB instigates inflammation, we have quantified functional changes in
circulating leukocytes using unbiased and comprehensive ‘omics approaches. Recently, we have measured
global gene expression changes that occur in neonatal
patients during and after CPB exposure using RNA sequencing.4 In this report, we examine the microRNA
(miRNA) changes that occur in neonatal patients with
CPB. miRNAs are small noncoding RNAs that generally bind to the 3’ untranslated regions of messenger
RNA (mRNA) based on complimentary base pairing
to target sites. miRNAs suppress gene expression
through inhibition of protein translation and/or promoting degradation of the target mRNAs.5 miRNAs modulate the protein levels of their target genes by either
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attenuating mRNA translation and/or promoting degradation of the target mRNAs.6 Through disruption of
these target genes, miRNAs play a vital role in numerous cellular and biological processes, including inflammatory signaling, and have been demonstrated to be
differentially expressed in many human diseases, such
as cardiovascular diseases.7
There has been great interest in identifying miRNA
biomarkers for post-CPB complications. For example,
miRNAs have been studied as biomarkers of myocardial injury.8,9 Currently, a limited amount is known
about the miRNA changes that occur in leukocytes in
response to CPB. This knowledge gap is significant
since leukocytes are crucial regulators of inflammation.
Understanding global changes of miRNA in leukocytes
is a critical step to better understand the mechanisms
of CPB-induced inflammation.
We performed a comprehensive unbiased profiling
of miRNA expression from pediatric patient leukocytes.
Blood samples were collected pre-
bypass, during
bypass, and post-bypass surgery at 7 different time
points from 5 infants with congenital heart diseases
undergoing CPB surgery. Leukocytes were isolated
from whole blood from each set of patient samples and
miRNA levels were subsequently quantified by high-
throughput small RNA sequencing. This study aimed
to characterize CPB-affected leukocyte miRNA profiles
and to holistically analyze how differential expression
of these miRNAs may impact target gene expression
and corresponding changes in biological pathways.

METHODS
The data that support the findings of this study are
available from the corresponding author on reasonable request.

Human Blood Samples
Pediatric patients aged <1 month with different congenital heart defects requiring repair utilizing CPB
were enrolled in our study at Mercy’s Children Hospital
(Kansas City, MO) (institutional review board protocol
number 14110493). Written informed consent was received from participants’ parents or legal guardians
before inclusion into the study. A standard CPB protocol was used in all of the patients. The approach in
all cases was via median sternotomy. Aortic cannulation was used for the arterial access, with either single
venous cannula being placed in the right atrium or bicaval cannulation, depending on the type of the defect
requiring repair. The CPB circuit was blood primed,
and standard additives included methylprednisolone,
sodium bicarbonate, cefazolin, and tranexamic acid.
After initiation of CPB, the patients were cooled to 18 to
30 °C. Mean perfusion pressure was maintained at 25
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to 35 mm Hg, and the minimum hematocrit was kept
at 24%. On completion of repair, the patients were rewarmed and weaned from CPB. Modified ultrafiltration
was performed in all of the patients after weaning from
CPB. Blood samples of 2.5 mL were collected from an
indwelling patient line or from the CPB pump, dependent on the time of the blood draw (for blood draws performed while the patient was on CPB, these samples
were pulled from the CPB pump). These samples were
collected in EDTA tubes at 7 time points: before CPB,
1 hour into CPB, at the end of CPB, at the end of modified ultrafiltration, and 1 hour, 8 hours, and 24 hours
during postoperative recovery. Blood was centrifuged
at 1000g for 20 minutes at room temperature, and
plasma was removed. Red blood cells were lysed in
RNase-free red blood cell lysis solution (PerfectPure
RNA blood kit, 5Prime) for 5 minutes at room temperature. The tubes were centrifuged at 2000g for 5 minutes at room temperature. The pellets of nucleated
cells were lysed in the cell lysis buffer and immediately
stored at −80 °C until RNA extraction. The design and
time course of the study are illustrated in Figure 1A.
Patient demographics are shown in Table 1.

miRNA Sequencing
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Total RNA from the nucleated cells was extracted
using a MirVana RNA extraction kit (Invitrogen). The
concentration and quality of total RNA for each sample
were quantified and evaluated by spectrophotometry
(Epoch; Thermo Scientific) and automated chip electrophoresis analyses (Experion, BioRad), respectively.
Each sample met the quality standards of a 260/280
ratio >2.0 and an RNA integrity number >9. Illumina
TruSeq RNA libraries were prepared from 1 μg of
total RNA and sequenced to generate 50 base pair
single-end reads using a HiSeq 1500 (Illumina) at the
Children’s Mercy OMICs Research Core Lab (Kansas
City, MO).

Bioinformatics
Small RNA sequencing data sets were analyzed using
the TIGER pipeline.10 Briefly, raw reads were preprocessed for quality control using FastQC ( www.bioin
formatics.babraham.ac.uk/projects/fastqc ). Cutadapt
(v2.9) was used to trim 3′ adapters and reads <16
nucleotides in length were removed.11 Preprocessed
small RNA reads were collapsed into nonredundant
identical files and aligned to the human genome using
bowtie (v1.2.3) allowing 1 mismatch.12 For miRNAs,
nontemplated additions were clipped from the 3′ terminal end, and small RNA reads overlapping mature
miRNA coordinates were counted allowing for offset
positions −2, −1, 0, +1, and +2. Results were reported
as raw read count and reads per million total reads.
Our RNA sequencing results were processed and
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analyzed using DEseq2 (v1.24.0), which is a standardized approach to RNA sequencing analysis13 with
>36 000 citations to date. We performed adjustment for multiple comparisons using the Benjamini-
Hotchberg approach.14 miRNAs were considered
statistically significant at a false discovery rate (FDR)–
adjusted P<0.05. miRNAs were considered to be significantly altered during either surgery or recovery if
there were significant differences for at least one time
point compared with baseline within each respective stage of CPB (surgery or recovery). A cutoff of 25
reads per million was used to filter out any miRNAs
with low expression. Differentially expressed miRNAs
were manually clustered based on the directionality of the log fold change and visualized using the R
package “pheatmap” (version 1.0.12, R Foundation
for Statistical Computing) (https://www.rdocumenta
tion.org/packag es/pheatm ap/versio ns/1.0.12/topic
s/pheatmap). Volcano plots and other miRNA data
visualization were generated by the TIGER pipeline.10

Identification of Putative miRNA Targets
Putative mRNA targets for miRNAs within each cluster were assessed using TargetScan software (v7.2,
targetscan.org), which predicts canonical targeting of
miRNAs based on 14 features.15 For cluster 3, which
contained >10 miRNAs, we included the top 10 miRNAs based on log fold change. All mRNA targets that
were not present in the paired total (mRNA) RNA sequencing data (n=12 709 genes) were removed. We
performed additional filtering using the absolute value
of the “context++” score, which is a metric of miRNA
target prediction accuracy used by TargetScan.15 For
each miRNA, we removed all putative targets with a
context++ score of 0. We also eliminated all mRNAs
that were not present in our ancillary mRNA analysis. We then selected the top 200 genes (based on
context++ score). This filtering ensured that only the
highest quality relationships were validated. The list
of gene targets from each filtering step is provided in
Table S1.

Pathway Enrichment Analysis of miRNA
Target Genes
We performed pathway enrichment analysis of the
genes regulated by each cluster of miRNAs using the
EnrichR R package (v2.1).16 For this analysis, we included only the top 200 genes (based on context++
score) for each miRNA. Through Enrichr, we analyzed
Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathways (excluding KEGG “Human Disease”
pathways). Pathways were considered statistically significant with an FDR-
adjusted P<0.05. miRNA-gene
pathway networks were visualized using cytoscape
(version 3.7.2).17
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All data were analyzed and visualized using R
(v4.0.3; R Foundation for Statistical Computing).

Cytokine-Receptor Networks
A subnetwork of receptor-
ligand networks was
generated for target genes using the Fantom5

database,18 which contained 708 ligands and 691 receptors. We performed a subanalysis of predefined
cytokines, chemokines, and integrin/adhesion molecules from within this receptor ligand network, based
on the class of molecules known to be mediators of
inflammation.
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Figure 1. Changes in microRNA (miRNA) expression during and after cardiopulmonary bypass (CPB).
A, The design and time course of the study. Neonates with different congenital heart diseases underwent CPB surgery that lasted 1.4 to
2.7 hours on average, followed by a short duration of modified ultrafiltration (MUF). Body temperature was cooled down to 18 to 30 °C
during surgery and quickly rewarmed to 37 °C after MUF. Blood samples were collected at 7 time points; miRNA from isolated nucleated
cells were submitted for sequencing (n=5 patients). The number of miRNAs were significantly downregulated or upregulated at different
time points compared with the expression level before surgery (CPB-0h). Significance was defined as false discovery rate–adjusted
P<0.05. B, A total of 54 miRNAs were divided into 3 clusters: cluster 1 with miRNAs upregulated in both phases, cluster 2 with miRNAs
downregulated in both phases, and cluster 3 with miRNAs downregulated in the surgery phase but upregulated in the recovery phase.
The heatmap shows the log2 fold changes in miRNAs in each cluster compared with before CPB. C, Bar plot showing the total number
of messenger RNA (mRNA) targets within each cluster. A subset of the targets was previously associated with CPB.4 Only the top 200
targets for each miRNA was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (C). The number of mRNA
targets for each individual miRNA are presented in Table S1. D, Overlapping and distinct target genes within each cluster that were
previously associated with CPB.4 CPB indicates Cardiopulmonary bypass; DE, differentially expressed; MUF, modified ultrafiltration.

RESULTS
miRNA Sequencing Analysis of Total
Patient Nucleated Cells Throughout CPB
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To characterize the miRNA expression profiles of patient blood affected by CPB, miRNA sequencing analysis was performed on RNA-isolated miRNA from total
nucleated cells of 5 neonate patients undergoing CPB
surgery (Table 1). Neonates with varying congenital
heart diseases (Table 1) underwent CPB surgery (bypass time range, 86–161 minutes; mean bypass time,
133 minutes [SD 37.33 minutes]), outlined in Figure 1A,
with blood samples collected at 7 different time points
before, during, and after CPB. miRNAs contributed
to >60% of the small noncoding RNAs present in
the blood collected during these times (Figure S1A).
Detection of unique miRNAs were characterized as
normalized expression in reads per million averaged
over all 5 patient samples, within each CPB time point.
The 4 most abundant miRNAs across all time points
were hsa-miR-486-5p, hsa-miR-92a-3p, hsa-miR-
451a, and hsa-miR-16-5p (Figure S1B).

Identification of Differentially Expressed
miRNAs in Different Stages of CPB
To obtain a better understanding of how CPB affects
miRNA expression, we compared the expression of miRNAs at surgery and recovery time points with the pre-
CPB time point (before CPB). Differentially expressed
miRNAs were identified through generalized linear regression models within DEseq2.12 Within each time point, we
observed that there were more differentially expressed
miRNAs that were significantly downregulated compared
with baseline than miRNAs that were upregulated compared with baseline (Figure 1A). Forty-two of these miRNAs had significantly altered expression at one time point
during surgery compared with baseline, 54 miRNAs had
significantly altered expression both during bypass and
after bypass, and 13 miRNAs had altered expression
compared with pre-CPB only in the recovery from CPB
phase, using a cutoff for significance of an FDR-adjusted
P<0.05 and a reads per million of >25.

To determine the effect of CPB on miRNA expression, the 54 miRNAs had significant modulation of expression at least one time point in both surgery and
recovery were clustered into 3 groups (Table S2) based
on their expression patterns throughout the course of
CPB and recovery (Figure 1B). Cluster 2 had a total
of 41 miRNAs with significantly decreased expression
based upon our clustering threshold. The top 10 miRNAs based upon fold change are listed in Figure 1B.
Cluster 1 (green) represents the miRNAs that remained
significantly upregulated in both CPB and recovery
phases (Figure 1B), cluster 2 (pink) represents the miRNAs that remained significantly downregulated in both
CPB and recovery, and cluster 3 (purple) represents
the miRNAs that were significantly downregulated in
at least one time point during CPB and significantly
upregulated in at least one time point in recovery.
We used the TargetScan database to identify putative mRNA targets of the miRNAs within each of the 3
clusters. The number of genes associated with each
miRNA and within each cluster is displayed in Table S1.
We filtered out genes that were not present in a parallel mRNA sequencing analysis done by our group.4
(Figure 1C).
In a previous study using a separate population,
we identified 2688 genes that exhibited temporal dysregulation after CPB, which were categorized into 5
distinct groups.4 We expanded on this analysis to investigate relationships between these differentially expressed genes (DEGs) and the miRNA target genes
identified in this analysis. A total of 1046 of these 2688
DEGs (38.9%) were reported targets of differentially expressed miRNAs, as shown in Table 2 and Figure 1C.
Seventy DEGs were targeted by miRNAs in all 3 clusters, 48 DEGs were targeted by miRNAs in clusters 1
and 3, 60 mRNAs were targeted by miRNAs in clusters 1 and 2, 208 DEGs were targeted by miRNAs in
clusters 2 and 3, 75 DEGs were targeted by miRNAs
in cluster 1 alone, 250 DEGs were targeted by miRNAs in cluster 3 alone, and 335 DEGs were targeted
by miRNAs in cluster 2 alone (Figure 1D). Many of
these DEGs were targeted by multiple miRNAs within
the same cluster. miRNA target genes contained DEGs
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Table 1. Patient Demographics
ID

Age, d

Weight, kg

Sex

Diagnosis

Lowest temp, °C

Surgery
time, min

Bypass time, min

1

5

3.3

Male

TGA, IVS, ASD

27.4

270

161

2

5

3.3

Male

HLHS, PDA, ASD

18.2

234

158

3

19

2.7

Female

TAPVC

18.0

163

86

4

12

3.4

Female

TAPVC

21.4

173

99

5

4

3.9

Male

HLHS, PDA

17.6

295

161

ASD indicates atrial septal defect; HLHS, hypoplastic left heart syndrome; IVS, intact ventricular septum; PDA, patent ductus arteriosis; TAPVC, total
anomalous pulmonary venous return; and TGA, transposition of the great artery.

across all 5 mRNA categories (Table 2), with most miRNAs across all clusters targeting genes in the “blue”
category (indicating gene expression downregulated
across all time points) or “red” category (ie, gene expression increased then decreased). Thus, these
changes in miRNA expression may be attributable to
some of the previously observed changes in gene expression after CPB.

KEGG Pathway and Target Gene Analysis
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To identify biologic pathways that were modulated by
miRNA clusters, we performed KEGG biological pathways analysis. For this analysis, we used the top 200
target genes for every miRNA based on context score.
Overall, we observed that the target genes of these
miRNAs were involved in the cell growth and death,
cellular community, immune, and signal transduction
KEGG subgroups (Figure 2). MiRNAs from cluster 1
targeted 512 genes that were enriched with the p53
signaling pathway and the cell cycle pathway (FDR-
adjusted P<0.05), which are both involved in cellular
growth and death (Figure 2). MiRNAs from cluster 2
targeted 1708 genes that were enriched within 32 different biological pathways (Figure 2). Several pathways
related to immunity, such as phagocytosis, B-cell receptors, and T-cell receptors, were identified as being
modulated by this cluster. The most significantly enriched pathway was for neurotrophin signaling. Nine
of these pathways were signal transduction pathways,
and 6 of these pathways were pathways related to the
immune system (Figure 2). MiRNAs from cluster 3 targeted 1430 genes that were enriched with 5 different

biological pathways. We also examined similarities and
differences in the pathways targeted by these miRNAs.
The p53 signaling pathway was enriched for genes,
which were targets of miRNAs in both cluster 1 and
cluster 2. There were no overlapping pathways between clusters 1 and 3. There were 4 pathways that
overlapped between clusters 2 and 3. Overall, the
most statistically significant pathway for each cluster were those related to the P53 signaling pathway
(FDR-adjusted P=4.77×10−5, cluster l), the Fc gamma
R-
mediated phagocytosis pathway (FDR-
adjusted
3.44×10−4, cluster 2) (Figure 2), and the neurotrophin
signaling pathway (FDR-adjusted 6.84×10−3, cluster 3).
From our previous research, we have demonstrated
that MEK/ERK signaling is important for CPB-induced
expression of interleukin (IL) 8 and tumor necrosis factor α (TNF-α).4 miRNAs from cluster 2 were predicted
targets of 38 genes in the mitogen-activated protein
kinase (MAPK) pathway, and this pathway was significantly enriched for these genes (P<0.05). Some of the
miRNA target genes included regulatory kinases of differentially expressed mRNAs found in our corresponding mRNA sequencing data (Figure 3).4

Cytokine-Receptor Networks
Since the many KEGG pathways enriched for the
miRNA target genes involved immune signaling, including the chemokine signaling pathway, we generated
a subnetwork of all receptor-ligand network reactions
for our miRNA target genes using the FANTOM5 database.17 Overall, cluster 1 was a potential regulator of
17 ligands and 11 receptors, cluster 3 was a potential

Table 2. Proportion of Target Genes in Each miRNA Cluster That Were Differentially Expressed in a Previous Analysis 4
Blue (n=775)

Orange (n=435)

Red (n=640)

Sky blue (n=422)

Yellow (n=407)

mRNA/miRNA
cluster

No. of
mRNAs

%

No. of
mRNAs

%

No. of
mRNAs

%

No. of
mRNAs

%

No. of
mRNAs

%

Cluster 1

88

11.4

29

3.7

68

8.8

35

4.5

38

4.9

Cluster 2

263

33.9

157

20.3

281

36.3

143

18.5

146

18.8

Cluster 3

198

25.5

117

15.1

244

31.5

98

12.6

100

12.9

No cluster

511

65.9

270

34.8

325

41.9

269

34.7

258

33.3

miRNA indicates microRNA; and mRNA, messenger RNA.
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Figure 2. Pathway enrichment analysis of the microRNA (miRNA) target genes in each cluster.
The heatmap showing significant Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathways enriched for the top genes
regulated by the miRNAs in each cluster. The numbers indicate the adjusted P-values for the pathways. FDR indicates false discovery
rate; MAPK, mitogen-activated protein kinase pathway; and VEGF, vascular endothelial growth factor.

regulator of 43 ligands and 31 receptors, and cluster 2
was a potential regulator of 47 receptors and 25 ligands
(Table S1). We performed a targeted analysis by looking at different mediators of inflammation associated
with each of the miRNA targets from each cluster. We
filtered target genes of each miRNA by cytokines and
their receptors (Figure 4A), chemokines and their receptors (Figure 4B), and integrin receptors and adhesion

molecules (Figure 4C). The color code of each miRNA
denotes which cluster each is derived from.

DISCUSSION
miRNAs play important roles in post-
transcriptional
regulation of target genes. Thus, understanding how
miRNA levels in leukocytes fluctuate during and after
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Figure 3. Targeted genes in the mitogen-activated protein kinase pathway (MAPK).
Genes in the MAPK pathway, which are targets of the differentially expressed microRNA (miRNA) are highlighted in yellow. Genes
predicted as the regulatory kinases of differentially expressed mRNAs in the matched mRNA sequencing data set are highlighted with
the red border.

CPB may significantly help to both advance the understanding of the mechanisms that underpin CPB-
associated inflammation and develop biomarkers of
CPB-
related complications. To our knowledge, this
study is the first to characterize the novel global miRNA
changes that occur in circulating leukocytes of patients
with CPB. The data set presented here significantly
advanced the state of knowledge since the previously
reported studies (Table S3) examined only a limited
number of miRNAs change in patients with CPB using
mainly serum or plasma samples. Our study specifically
examined changes in circulating nucleated cells, a cell
population that is an important driver of inflammation.
In addition, the global profiling of all miRNA changes in
an unbiased manner significantly advances the understanding of how circulating leukocytes are responding
to CPB. The data presented in this study, especially regarding the miRNAs that are predicted to facilitate the
resolution of inflammation, may form the basis of novel
therapeutic and risk stratification strategies.

Given that miRNA typically reduce the protein levels
of their target genes,6 our data suggest that miRNAs
are involved in the development and resolution of CPB-
associated inflammation. During CPB, the changes in
miRNA levels promote inflammation. miRNAs that are
upregulated during CPB (cluster 1) target genes that
are typically anti-inflammatory, such as IL-10 and IL-
1R2 (Figure 4A). At the same time, miRNAs that are
downregulated during CPB (clusters 2 and 3) target receptors for key inflammatory signaling pathways, such
as TNF-α and IL-8 (Figure 4A and 4B). These changes
have the net result of increasing the activity of inflammatory pathways.
The role of the members of cluster 2, miRNAs that
are decreased during and after CPB, is especially interesting given that this cluster is predicted to uniquely
modulate pathways and receptors involved with inflammation. As these miRNAs generally are thought to
decrease gene expression, reduction of expression of
these negative regulators during and after surgery may
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Figure 4. Receptor-ligand networks for the target genes in each cluster.
Analysis of receptor-ligand networks were performed for target genes using the Fantom5 database. The networks of cytokines and
receptors (A), chemokines and receptors (B) and integrin receptors and adhesion molecules (C) targeted by the microRNA (miRNA) in
each cluster were demonstrated. IL indicates interleukin.

lead to corresponding increased expression of their
target genes involved in immune regulation. As shown
in Figure 2, members of this cluster are predicted to repress pathways such as leukocyte migration, chemokine signaling, and MAPK signaling. Cytokines that
are activated during CPB,4,19–25 such as IL-6, IL-8, and
TNF-α, or their receptors are targeted by members of
this cluster of miRNAs.
Cluster 3, miRNAs that are decreased during CPB
and rise after CPB, modulate genes related to cytokine signaling. For example, miR-223-3p (a member
of cluster 3) has been shown to target IL-6.26 miR-23a
is an miRNA that targets and inhibits proinflammatory

cytokine IL-
8 via signal transducer and activator of
transcription 3 inhibition.27 The IL-8 receptor, CXCR1, is
predicted to be targeted by miR-1248, while another of
its receptors, CXCR2 is targeted by miR-223.26 miRNA-
29-3p28 and miR-223-5p29 target TNFRSF1, which encodes a key receptor for TNF signaling. Based on these
data, we believe that the members of miRNA cluster 3
play important roles in modulating CPB-associated inflammation in circulating leukocytes.
Our study is limited by its small sample size; however, there are clear patterns of specific miRNA differential expression among all patient samples, based on
dense temporal mapping and comparisons within each
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patient. We also based our analyses on the assumption that miRNAs negatively regulate gene expression,
when in reality this relationship is more complex.6 More
research is necessary to validate and isolate specific
functions of these miRNAs. The sample size precludes our ability to correlate the miRNA changes to
clinical parameters—such as steroid treatment, patient
age, cardiac lesion, or clinical outcomes. Some of the
strengths of this study are the global miRNA profiling
of circulating miRNAs at several time points during
and after CPB. It is important to expand our understanding the role that miRNAs play in the context of
CPB-induced inflammation to help us further uncover
all of the mechanisms in which inflammation is induced
and operates. Furthermore, miRNAs may also have the
potential to be a noninvasive, nonpharmacologic treatment in moderating this inflammation.
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Table S1. Ligands and receptors as target genes of differentially expressed miRNAs in each
cluster
Cluster

miRNA

let-7-5p

Receptors

Ligands

TGFBR1, ADRB2, FAS, CCR7,

EDN1, IL10, S100A8,

IGF1R, PGRMC1, ITGB3, TGFBR3,

CCL3L1, FASLG, CCL3,

FAS

CCL3L3

EDNRB, VLDLR

HBEGF

Cluster 1
miR-182-5p

IL1R2, LEPR, IFNGR1, ASGR2,
miR-183-3p

BMP3, LPL, LYZ
KLRD1, ITGA8, CD109
DDR1, BCAM, CELSR1, FZD6,

miR-199-5p

ITGA8, ACVR1B, PLXNC1, ACVR1B,

LIN7C, HG

ACVR1B
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miR-582-3p

TFRC, BMPR2, TFRC

TNFSF4

miR-223-3p

IL6ST, ACVR2A, SCARB1, SDC2

HSP90B1, SORBS1
TNFSF14, TIMP3, TNFSF10,

DPP4, CD177, ERAP1, LRP8, DPP4,
miR-223-5p

OLAH, ICAM4, HSPA1A,
CD177, ERAP1, LRP8
EFNB2, FBN1

Cluster 3
ROBO1, TNFRSF1A, CNR1, F11R,

COL1A1, COL3A1, COL7A1,

CNR1

PDGFC, VEGFA, COL6A3

ABCA1, NRXN3

PROK2, CXCL5

miR-29-3p

miR-23-3p

CD93, EDNRB, CXCR5, VANGL1,
miR-181a-3p

COL9A2, APP, ADAM10
F2R

miR-24-3p

LMBR1L, SIRPA

FASLG, LAMB3

KLRK1, CD81, EPHB6, CD28,

HBEGF, HMGB1, PDGFB,

CXCR1, ADCY7, LEPR

DUSP18

miR-1248

ORAI2, IFNAR1, GFRA2, MGRN1,
TIMP2

miR-941
TLR6, IL15RA
miR-127-3p

ITGA6

DLK1

miR-136-3p

ERAP1, IL6R, NPTN, CANX, NPTN

CLCF1

miR-144-5p

TMEM67, F2R, TLR2, TFR2, CD3G

RELN

ADORA2B, NRP2, CD28, ST14,
miR-27-3p

HBEGF, COLQ, SEMA6A
BMPR2

miR-381-3p

IL15RA, LRRC4, SLC18A2

PDAP1, PDGFC

S1PR1, LRP6, PLXNC1, TGFBR3,

CXCL1, CALM1, LIN7C,

MYLK, ACVR2B

SEMA4F

miR-409-3p
Cluster 2
NRXN3, PLXNA2, ITGA9, CXCR5,
miR-410-3p

HMGB1, ADM, RGMB
MCAM, IFNAR2

miR-411-5p

TGFBR2

CLEC11A
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CXCR2, TFRC, DYSF, OLR1,
miR-654-3p

ITGAM, ITGAV, SLC37A1, KCNJ15,

MST1, FLT3LG, APP

KLRC1, CNR1, KLRC2, PLXNA4
VEGFB, CALM3, LTBP3,
miR-374a-3p

KLRG1, LGR4, AMFR, CCR2
EDIL3, B2M, LPL

Table S2. The number of miRNA gene targets used in sub-analyses
miRNA
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miR-183-3p
let-7-5p
miR-182-5p
miR-654-3p
miR-27-3p
miR-136-3p
miR-374a-3p
miR-144-5p
miR-410-3p
miR-409-3p
miR-381-3p
miR-411-5p.1
miR-127-3p
miR-1248
miR-582-3p
miR-29-3p
miR-23-3p
miR-199-5p
miR-223-5p
miR-223-3p
miR-941
miR-181a-3p
miR-24-3p

Cluster
C1

C2

C3

Target Genes
(Targetscan)
2599
332
172
2523
1092
1155
1355
938
604
316
128
123
25
2843
1622
755
713
634
994
415
387
322
119

Target Genes with
|Context Score|>0
1722
332
172
1921
1055
1137
737
715
558
286
128
118
25
2013
1622
755
713
610
662
405
362
322
119

Target Genes Present in
mRNA Analysis*
1128
237
119
1264
751
726
487
485
395
199
93
89
17
1347
1101
562
517
462
432
329
222
201
81

Target Genes
significantly DE*
194
41
23
232
135
128
73
79
68
21
13
7
1
223
174
112
87
64
83
60
41
49
14

Genes used for KEGG
Pathway Enrichment
200
200
119
200
200
200
200
200
200
199
93
89
17
200
200
200
200
200
200
200
200
200
81

Table S3. Plasma and serum miRNAs reported in the literature as biomarkers for
complications in CPB surgery
miRNA

Age

Elevation time point

Pediatric

6-24h post CPB

miR-208a/b

Associated complications

Reference

Myocardial injury

miR-499

30,31

Length of hospital stay

miR-223

Adult

2-6h after start of CPB

Inflammation

32

miR-21

Pediatric

6-24h post CPB

Acute kidney injury

33

miR-1

Adult

1-24h post CPB

Myocardial injury

34

Adult

CPB & 4h post CPB

Myocardial injury

35

Adult

8-16h post CPB

Acute lung injury

36

Adult

1-6h post CPB

Myocardial injury

37

miR-210
miR-16
miR-320
miR-200c
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miR-205
miR-133a
miR-499

Figure S1. miRNA sequencing analysis of total nucleated cells from pediatric patients
undergoing CPB

(A) Pie chart showing the mean distribution of different small RNA species in all sequenced
samples. (B) Normalized expression in Reads per millions (RPM) of the most abundant miRNAs
detected in patient samples at different time points.
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